Tag: GSK
-
GSK lifts annual forecasts once more, powered by sturdy vaccine launch
By Eva Mathews (Reuters) -GSK raised its full-year revenue and gross sales forecasts for a second time on Wednesday, following the sturdy launch of its respiratory syncytial virus (RSV) vaccine in america. GSK is betting on RSV vaccine Arexvy to be its subsequent blockbuster drugs because it grapples with a mixture of patent expiries and…